We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Acorda Therapeutics Inc | NASDAQ:ACOR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.661 | 0.565 | 0.5878 | 0 | 01:00:00 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 5)
ACORDA THERAPEUTICS, INC.
00484M106
/x/ Rule 13d-1(b)
/ / Rule 13d-1(c)
/ / Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover
page shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act")
or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
1. Names of Reporting Persons and I.R.S. Identification No.
UBS Group AG (for the benefit and on behalf of the UBS Global Asset Management division of UBS Group AG, see Item 7)
Switzerland ----------------------------------------------------------- Number of 5. Sole Voting Power 2,709,027 Shares Bene- 6. Shared Voting Power 0 ficially 7. Sole Dispositive Power 0 Owned by Each 8. Shared Dispositive Power 2,922,722 |
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
2,922,722*
Cusip 00484M106
Item 1(a). Name of Issuer:
ACORDA THERAPEUTICS
Item 1(b). Address of Issuer's Principal Executive Offices:
7585 IRVINE CENTER DR
SUITE 100
IRVINE, CA 92618
Item 2(a) Name of Persons Filing:
UBS Group AG
Item 2(b) Address of Principal Business Office or, if none, Residence:
UBS Group AG's principal business office is:
Bahnhofstrasse 45
Zurich Switzerland
Item 2(c) Citizenship:
Incorporated by reference to Item 4 of the cover pages.
Item 2(d) Title of Class of Securities:
Common Stock (the "Common Stock")
Item 2(e) CUSIP Number:
00484M106
Item 3. Type of Person Filing:
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
Item 5. Ownership of Five Percent or Less of a Class:
Identification: UBS Global Asset Management (Americas) Inc. Classification: IA
In addition to UBS Group AG, the following UBS Global AM affiliates and subsidiaries are part of the UBS Global Asset Management division included in this filing: UBS AG, UBS Global Asset Management (Americas) Inc., UBS Global Asset Management Trust Company, UBS Global Asset Management (Canada) Inc., UBS Global Asset Management (Australia) Ltd., UBS Global Asset Management (Hong Kong) Limited, UBS Global Asset Management (Japan) Ltd., UBS Global Asset Management (Singapore) Ltd., UBS Global Asset Management (Taiwan) Ltd., UBS Global Asset Management (Deutschland) GmbH, UBS Global Asset Management (Italia) SGR SpA, UBS Global Asset Management (UK) Ltd., UBS Global Asset Management Life Limited, Hana Asset Management Co., Ltd., and CCR Asset Management S.A.
UBS Group AG acquired UBS AG through the completion of a share transfer offer on 28 November 2014 in which the shareholders of UBS AG became shareholders of UBS Group AG and their shares in UBS AG were transferred to UBS Group AG. As a result, UBS Group AG controls UBS AG.
UBS Global AM is composed of wholly-owned subsidiaries and branches of UBS Group AG. UBS Group AG is reporting direct and indirect beneficial ownership of holdings. None of the reporting persons affirm the existence of a group within the meaning of Rule 13d-5(b)(1).
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: June 9, 2015
UBS Group AG
By: /s/ Mark F. Kemper Mark F. Kemper Attorney-in-Fact pursuant to Power of Attorney, attached as Exhibit 1, for the UBS Global Asset Management division of UBS Group AG By: /s/ Michael J. Calhoun Michael J. Calhoun Attorney-in-Fact pursuant to Power of Attorney, attached as Exhibit 1, for the UBS Global Asset Management division of UBS Group AG |
EXHIBIT INDEX
Exhibit Number Exhibit Description
1 Power of Attorney dated as of January 12, 2015
EXHIBIT 1
POWER OF ATTORNEY
Each of the following representatives of UBS Global Asset Management (Americas) Inc. is hereby appointed as agent and attorney-in-fact with power and authority to sign US Regulatory Filings, including Schedule 13G and Form 13F, on behalf of UBS Group AG, and its affiliates in the UBS Global Asset Management division:
Joseph Allessie
James Barling
Michael J. Calhoun
Mark F. Kemper
John Moore
Barry Mullen
Jennifer Wiley
All prior powers of attorney relating to the subject matter of this Power of Attorney are hereby revoked. This Power of Attorney is limited to the circumstances set forth herein and may be revoked, in whole or in part, at any time. If a person identified above ceases to perform services for UBS Global Asset Management for any reason, this Power of Attorney shall be automatically revoked with respect to that person. Nothing in this Power of Attorney is intended to limit the authority of any other persons to sign documents relating to the subject matter hereof to the extent permitted by UBS Group Policy or otherwise.
APPROVED:
Date: As of January 12, 2015 /s/ Mario Cueni Mario Cueni UBS Global Asset Management General Counsel Group Managing Director /s/ Shawn Lytle Shawn Lytle UBS Global Asset Management Head of Americas Group Managing Director |
1 Year Acorda Therapeutics Chart |
1 Month Acorda Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions